Acute Myeloid Leukemia — Trials

Acute Myeloid Leukemia — Trials · CancerIndex

Clinical trials

Registered studies

2,962 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 789
Recruiting: 466
Ph III recruiting: 45
Growth YoY: +5%
Industry share: 19%
Top sponsor: M.D. Anderson Cancer Center
Termination share: 38.9%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (534)

clinicaltrialsPublishedShowing 1–4 of 4 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03070093	Expanded Access Study of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)	approved for marketing	—	—	Astellas Pharma Global Development, Inc.INDUSTRY	3	Apr 20, 2021	clinicaltrials
NCT03723135	Expanded Access for CC-486	approved for marketing	—	—	CelgeneINDUSTRY	1